Date: Nov 2, 2024 01:00 AM
Fee
CE Hours
CE Units
Registration closes on Dec 02, 2024 01:00 AM
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
Registration start from
11/02/2024
11/02/2024
Objectives
- Recognize different types of carcinoid tumors and their disease pathology
- Identify common treatment regimens used and carcinoid tumors
- Describe side effect management of treatment regimens used in carcinoid tumors
Speaker(s)/Author(s)
Amanda Cass |
Activity Number
0064-9999-24-220-L01-PCE Hours
11/02/2024
Registration start from
11/02/2024
11/02/2024
Objectives
- Define circulating tumor DNA (ctDNA)
- Describe strengths and limitations of utilizing ctDNA as a cancer biomarker
- Discuss applications of ctDNA for detecting minimal residual disease in solid tumors
Speaker(s)/Author(s)
Sarah Cimino |
Activity Number
0064-9999-24-221-L01-PCE Hours
11/02/2024
Registration start from
11/02/2024
11/02/2024
Objectives
- Review the evidence behind perioperative immune checkpoint inhibitors for early stage non-small cell lung cancer
- Discuss a treatment plan incorporating perioperative immune checkpoint inhibitors for appropriate patients
Speaker(s)/Author(s)
Kori Holman-Daniels |
Activity Number
0064-9999-24-222-L01-PCE Hours
11/02/2024
Registration start from
11/02/2024
11/02/2024
Objectives
- Review novel and expanded indication medications for AML & MDS
- Compare trial data for medications used in AML/MDS
- Discuss novel adverse effects associated with new therapies
- Select treatment plans for patient cases based on the data reviewed
Speaker(s)/Author(s)
Dennis Marjoncu, PharmD, BCOP
|
Activity Number
0064-9999-24-223-L01-PCE Hours
11/02/2024
Registration start from
11/02/2024
11/02/2024
Objectives
- Recall the efficacy, dosing, and safety of current and emerging therapies for early stage melanoma
- Identify strategies to personalize treatment based on patient-specific factors to select the most appropriate therapy for early stage melanoma
Speaker(s)/Author(s)
Colleen McCabe |
Activity Number
0064-9999-24-224-L01-PCE Hours
11/02/2024
Registration start from
11/02/2024
11/02/2024
Objectives
- Review the current literature for the utilization of adjuvant CDK4/6 inhibitors in HR+, HER2- early stage breast cancer and understand the differences between abemaciclib and ribociclib usage
- Describe the evolving treatment landscape of HR+, HER2- metastatic breast cancer with the integration of more targeted therapies such as oral SERDs and AKT inhibitors and impact on treatment paradigm
- Explain the concept of "HER2 low" and ??ultra-low????and use of trastuzumab deruxtecan within metastatic HER2- breast cancer
Speaker(s)/Author(s)
Heather Moore |
Activity Number
0064-9999-24-225-L01-PCE Hours
11/02/2024
Registration start from
11/02/2024
11/02/2024
Objectives
- Describe the DISC (Dominance, Influence, Steadiness, Conscientiousness) framework and its relevance to pharmacist-patient interactions within oncology practice
- Compare the four primary behavioral styles within the DISC framework and their potential implications for communication with oncology patients
- Review practical strategies for adapting pharmacist-patient communication approaches based on the unique personality traits and communication preferences of oncology patients
- Identify active listening techniques to enhance empathy and rapport-building within encounters with oncology patients through utilization of the DISC framework
Speaker(s)/Author(s)
Gregory Sneed, PharmD
|
Activity Number
0064-9999-24-226-L01-PCE Hours
11/02/2024
Registration start from
11/02/2024
11/02/2024
Objectives
- Review the history and scope of the hazardous drug standards
- Describe the existing requirements and best practices for the current hazardous drug handling standards
- Cite potential barriers and solutions for the safe handling of hazardous drugs
Speaker(s)/Author(s)
Beatrice Turner, PharmD, BCPS
|
Activity Number
0064-9999-24-227-L01-PCE Hours
11/02/2024